JP6713472B2 - クロメノンモノカルボン酸トランスポータ阻害薬 - Google Patents
クロメノンモノカルボン酸トランスポータ阻害薬 Download PDFInfo
- Publication number
- JP6713472B2 JP6713472B2 JP2017538317A JP2017538317A JP6713472B2 JP 6713472 B2 JP6713472 B2 JP 6713472B2 JP 2017538317 A JP2017538317 A JP 2017538317A JP 2017538317 A JP2017538317 A JP 2017538317A JP 6713472 B2 JP6713472 B2 JP 6713472B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- ring
- formula
- fluoroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000000562 Monocarboxylic Acid Transporters Human genes 0.000 title claims description 14
- 101710204259 Monocarboxylic acid transporter Proteins 0.000 title claims description 12
- 239000003112 inhibitor Substances 0.000 title description 15
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 67
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 102100034068 Monocarboxylate transporter 1 Human genes 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 42
- 101000937642 Homo sapiens Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 claims description 36
- 101000590830 Homo sapiens Monocarboxylate transporter 1 Proteins 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 24
- 101000577126 Homo sapiens Monocarboxylate transporter 4 Proteins 0.000 claims description 23
- 102100025276 Monocarboxylate transporter 4 Human genes 0.000 claims description 23
- 101000577129 Homo sapiens Monocarboxylate transporter 5 Proteins 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 12
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 claims description 8
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 229940123208 Biguanide Drugs 0.000 claims description 4
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- 230000003178 anti-diabetic effect Effects 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 230000000155 isotopic effect Effects 0.000 claims description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 4
- 229960003105 metformin Drugs 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 2
- 101100545229 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ZDS2 gene Proteins 0.000 claims 1
- 101100167209 Ustilago maydis (strain 521 / FGSC 9021) CHS8 gene Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 105
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 71
- 238000005481 NMR spectroscopy Methods 0.000 description 60
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 51
- 238000004128 high performance liquid chromatography Methods 0.000 description 36
- 239000007787 solid Substances 0.000 description 32
- 230000029936 alkylation Effects 0.000 description 21
- 238000005804 alkylation reaction Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- -1 5-Hydroxy-2-isopropyl-4-oxo-4H-chromen-7-yl Chemical group 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 0 CC(C=N)=C(C=CC=C1)C1=* Chemical compound CC(C=N)=C(C=CC=C1)C1=* 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000012267 brine Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 101710124867 Malonyl CoA-acyl carrier protein transacylase Proteins 0.000 description 8
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 8
- 239000002168 alkylating agent Substances 0.000 description 8
- 229940100198 alkylating agent Drugs 0.000 description 8
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 239000012445 acidic reagent Substances 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101000577115 Homo sapiens Monocarboxylate transporter 2 Proteins 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- SIJLYRDVTMMSIP-UHFFFAOYSA-N 4-Bromo-1-butanol Chemical compound OCCCCBr SIJLYRDVTMMSIP-UHFFFAOYSA-N 0.000 description 4
- VMCYACFZYRHDTN-UHFFFAOYSA-N 5-hydroxy-4-oxo-2-propan-2-ylchromene-7-carboxylic acid Chemical compound OC1=C2C(C=C(OC2=CC(=C1)C(=O)O)C(C)C)=O VMCYACFZYRHDTN-UHFFFAOYSA-N 0.000 description 4
- FUSCDWDJZUWDOE-UHFFFAOYSA-N 5-hydroxy-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O FUSCDWDJZUWDOE-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 102100025272 Monocarboxylate transporter 2 Human genes 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- IMMSCHCNOMZFDV-UHFFFAOYSA-N [7-(hydroxymethyl)-4-oxo-2-propan-2-ylchromen-5-yl] acetate Chemical compound C(C)(=O)OC1=C2C(C=C(OC2=CC(=C1)CO)C(C)C)=O IMMSCHCNOMZFDV-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical group 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001414 amino alcohols Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 150000002148 esters Chemical group 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- GQRDUQOHSQEPBQ-UHFFFAOYSA-N (7-cyano-4-oxo-2-propan-2-ylchromen-5-yl) acetate Chemical compound C(C)(=O)OC1=C2C(C=C(OC2=CC(=C1)C#N)C(C)C)=O GQRDUQOHSQEPBQ-UHFFFAOYSA-N 0.000 description 3
- RZJGKPNCYQZFGR-UHFFFAOYSA-N 1-(bromomethyl)naphthalene Chemical compound C1=CC=C2C(CBr)=CC=CC2=C1 RZJGKPNCYQZFGR-UHFFFAOYSA-N 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical group C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 3
- VGFBRVLVWZEEIJ-UHFFFAOYSA-N 5,7-dihydroxy-2-propan-2-ylchromen-4-one Chemical compound C1=C(O)C=C2OC(C(C)C)=CC(=O)C2=C1O VGFBRVLVWZEEIJ-UHFFFAOYSA-N 0.000 description 3
- OHRKFWOROQUXAF-UHFFFAOYSA-N 5-(2,3-dihydroxypropoxy)-2-methyl-7-quinolin-4-yloxychromen-4-one Chemical compound OC(COC1=C2C(C=C(OC2=CC(=C1)OC1=CC=NC2=CC=CC=C12)C)=O)CO OHRKFWOROQUXAF-UHFFFAOYSA-N 0.000 description 3
- RKYXNJKEXJBHCG-UHFFFAOYSA-N 5-(3-hydroxypropoxy)-2-methyl-7-quinolin-4-yloxychromen-4-one Chemical compound OCCCOC1=C2C(C=C(OC2=CC(=C1)OC1=CC=NC2=CC=CC=C12)C)=O RKYXNJKEXJBHCG-UHFFFAOYSA-N 0.000 description 3
- DCPMOOWSMMHHSZ-UHFFFAOYSA-N 5-(4-hydroxybutoxy)-2-propan-2-yl-7-(quinolin-4-ylmethoxy)chromen-4-one Chemical compound OCCCCOC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=NC2=CC=CC=C12)C(C)C)=O DCPMOOWSMMHHSZ-UHFFFAOYSA-N 0.000 description 3
- GNGYPWCRMOTMSM-UHFFFAOYSA-N 5-(4-hydroxybutoxy)-7-(naphthalen-1-yloxymethyl)-2-propan-2-ylchromen-4-one Chemical compound OCCCCOC1=C2C(C=C(OC2=CC(=C1)COC1=CC=CC2=CC=CC=C12)C(C)C)=O GNGYPWCRMOTMSM-UHFFFAOYSA-N 0.000 description 3
- UQCUTHJIBQPNET-UHFFFAOYSA-N 5-acetyloxy-4-oxo-2-propan-2-ylchromene-7-carboxylic acid Chemical compound C(C)(=O)OC1=C2C(C=C(OC2=CC(=C1)C(=O)O)C(C)C)=O UQCUTHJIBQPNET-UHFFFAOYSA-N 0.000 description 3
- WHRHSMOIZUVYBL-UHFFFAOYSA-N 5-hydroxy-2-methyl-7-quinolin-4-yloxychromen-4-one Chemical compound OC1=C2C(C=C(OC2=CC(=C1)OC1=CC=NC2=CC=CC=C12)C)=O WHRHSMOIZUVYBL-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000006536 aerobic glycolysis Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 235000015838 chrysin Nutrition 0.000 description 3
- 229940043370 chrysin Drugs 0.000 description 3
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical group N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- XVUIMNRYRLJUNI-UHFFFAOYSA-N (5-hydroxy-4-oxo-2-propan-2-ylchromen-7-yl) trifluoromethanesulfonate Chemical compound CC(C)c1cc(=O)c2c(O)cc(OS(=O)(=O)C(F)(F)F)cc2o1 XVUIMNRYRLJUNI-UHFFFAOYSA-N 0.000 description 2
- 125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- XLEYFDVVXLMULC-UHFFFAOYSA-N 2',4',6'-trihydroxyacetophenone Chemical compound CC(=O)C1=C(O)C=C(O)C=C1O XLEYFDVVXLMULC-UHFFFAOYSA-N 0.000 description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- QJQXVPCIRZUOIP-UHFFFAOYSA-N 4-(bromomethyl)quinoline Chemical compound C1=CC=C2C(CBr)=CC=NC2=C1 QJQXVPCIRZUOIP-UHFFFAOYSA-N 0.000 description 2
- KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 2
- ZFUWVPSLHITBKV-UHFFFAOYSA-N 5-(2,3-dihydroxypropoxy)-2-phenyl-7-quinolin-4-yloxychromen-4-one Chemical compound OC(COC1=C2C(C=C(OC2=CC(=C1)OC1=CC=NC2=CC=CC=C12)C1=CC=CC=C1)=O)CO ZFUWVPSLHITBKV-UHFFFAOYSA-N 0.000 description 2
- HZMIZJUGPSMNFE-UHFFFAOYSA-N 5-(3-hydroxypropoxy)-2-phenyl-7-quinolin-4-yloxychromen-4-one Chemical compound OCCCOC1=C2C(C=C(OC2=CC(=C1)OC1=CC=NC2=CC=CC=C12)C1=CC=CC=C1)=O HZMIZJUGPSMNFE-UHFFFAOYSA-N 0.000 description 2
- ZVTIVBZRNNJNQL-UHFFFAOYSA-N 5-(3-hydroxypropoxy)-2-propan-2-yl-7-(quinolin-4-ylmethoxy)chromen-4-one Chemical compound OCCCOC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=NC2=CC=CC=C12)C(C)C)=O ZVTIVBZRNNJNQL-UHFFFAOYSA-N 0.000 description 2
- QDPYAIGDDBYEFL-UHFFFAOYSA-N 5-(3-hydroxypropoxy)-7-(naphthalen-1-ylmethoxy)-2-phenylchromen-4-one Chemical compound OCCCOC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1)=O QDPYAIGDDBYEFL-UHFFFAOYSA-N 0.000 description 2
- FSJAJYDHCGTEPA-UHFFFAOYSA-N 5-(4-hydroxybutoxy)-2-methyl-7-(naphthalen-1-ylmethoxy)chromen-4-one Chemical compound OCCCCOC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C)=O FSJAJYDHCGTEPA-UHFFFAOYSA-N 0.000 description 2
- VOEGYFBVNXYLKU-UHFFFAOYSA-N 5-(4-hydroxybutoxy)-7-(naphthalen-1-ylmethoxy)-2-phenylchromen-4-one Chemical compound OCCCCOC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1)=O VOEGYFBVNXYLKU-UHFFFAOYSA-N 0.000 description 2
- DCHXVBAAHTYKOE-UHFFFAOYSA-N 5-(4-hydroxybutoxy)-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCCCCOC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O DCHXVBAAHTYKOE-UHFFFAOYSA-N 0.000 description 2
- BYLXOSWMGRWNPM-UHFFFAOYSA-N 5-[2-chloro-5-(hydroxymethyl)phenyl]-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound ClC1=C(C=C(C=C1)CO)C1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O BYLXOSWMGRWNPM-UHFFFAOYSA-N 0.000 description 2
- ILGYHHXEGMWOBA-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-[4-(trifluoromethyl)pyridin-2-yl]oxychromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OC2=NC=CC(=C2)C(F)(F)F)C(C)C)=O)C=CC=C1 ILGYHHXEGMWOBA-UHFFFAOYSA-N 0.000 description 2
- RRLZPVKCKKRJKD-UHFFFAOYSA-N 5-hydroxy-2-phenyl-7-quinolin-4-yloxychromen-4-one Chemical compound OC1=C2C(C=C(OC2=CC(=C1)OC1=CC=NC2=CC=CC=C12)C1=CC=CC=C1)=O RRLZPVKCKKRJKD-UHFFFAOYSA-N 0.000 description 2
- UEJWFIASBMVBBC-UHFFFAOYSA-N 5-hydroxy-2-propan-2-yl-7-(quinolin-4-ylmethoxy)chromen-4-one Chemical compound OC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=NC2=CC=CC=C12)C(C)C)=O UEJWFIASBMVBBC-UHFFFAOYSA-N 0.000 description 2
- VTEICTJRZSWIJJ-UHFFFAOYSA-N 5-hydroxy-7-(naphthalen-1-yloxymethyl)-2-propan-2-ylchromen-4-one Chemical compound OC1=C2C(C=C(OC2=CC(=C1)COC1=CC=CC2=CC=CC=C12)C(C)C)=O VTEICTJRZSWIJJ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 102100032412 Basigin Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 108010041817 Monocarboxylic Acid Transporters Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- AGFYQCGVKPTVLB-UHFFFAOYSA-N [4-oxo-2-propan-2-yl-7-(trifluoromethylsulfonyloxy)chromen-5-yl] acetate Chemical compound C(C)(=O)OC1=C2C(C=C(OC2=CC(=C1)OS(=O)(=O)C(F)(F)F)C(C)C)=O AGFYQCGVKPTVLB-UHFFFAOYSA-N 0.000 description 2
- ZJHJTQDASUOKMK-UHFFFAOYSA-N [7-(naphthalen-1-yloxymethyl)-4-oxo-2-propan-2-ylchromen-5-yl] acetate Chemical compound C(C)(=O)OC1=C2C(C=C(OC2=CC(=C1)COC1=CC=CC2=CC=CC=C12)C(C)C)=O ZJHJTQDASUOKMK-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 229940126127 monocarboxylate transporter inhibitor Drugs 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 2
- 125000003367 polycyclic group Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- MLYAEBUAVSAKHK-UHFFFAOYSA-N 1-(chloromethyl)-3-(trifluoromethyl)benzene pyridine Chemical compound c1ccncc1.FC(F)(F)c1cccc(CCl)c1 MLYAEBUAVSAKHK-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- MUIYFRGQHOZAIE-UHFFFAOYSA-N 2-(7-cyano-4-oxo-2-propan-2-ylchromen-5-yl)acetic acid Chemical compound CC(C)C1=CC(=O)C2=C(C=C(C=C2O1)C#N)CC(=O)O MUIYFRGQHOZAIE-UHFFFAOYSA-N 0.000 description 1
- NNAYPIDFVQLEDK-UHFFFAOYSA-N 2-(bromomethyl)quinoline Chemical compound C1=CC=CC2=NC(CBr)=CC=C21 NNAYPIDFVQLEDK-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- RWNOTIJPCILYLX-UHFFFAOYSA-N 2-[7-(hydroxymethyl)-4-oxo-2-propan-2-ylchromen-5-yl]acetic acid Chemical compound CC(C)C1=CC(=O)C2=C(C=C(C=C2O1)CO)CC(=O)O RWNOTIJPCILYLX-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- RXATZPCCMYMPME-UHFFFAOYSA-N 2-chloro-3-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CN=C1Cl RXATZPCCMYMPME-UHFFFAOYSA-N 0.000 description 1
- JODJNDQSVFXRSD-UHFFFAOYSA-N 2-cyclopropyl-5-[[2-(hydroxymethyl)phenyl]methoxy]-7-(naphthalen-1-ylmethoxy)chromen-4-one Chemical compound C1(CC1)C=1OC2=CC(=CC(=C2C(C=1)=O)OCC1=C(C=CC=C1)CO)OCC1=CC=CC2=CC=CC=C12 JODJNDQSVFXRSD-UHFFFAOYSA-N 0.000 description 1
- PYVKFZJMILDAIS-UHFFFAOYSA-N 2-cyclopropyl-5-[[2-(hydroxymethyl)phenyl]methoxy]-7-[[2-(trifluoromethyl)pyridin-3-yl]methoxy]chromen-4-one Chemical compound C1(CC1)C=1OC2=CC(=CC(=C2C(C=1)=O)OCC1=C(C=CC=C1)CO)OCC=1C(=NC=CC=1)C(F)(F)F PYVKFZJMILDAIS-UHFFFAOYSA-N 0.000 description 1
- DFNQBXZKPUBEIX-UHFFFAOYSA-N 2-fluoro-4-(trifluoromethyl)pyridine Chemical compound FC1=CC(C(F)(F)F)=CC=N1 DFNQBXZKPUBEIX-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ZTGKHKPZSMMHNM-UHFFFAOYSA-N 3-(2-phenylethenyl)benzene-1,2-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(C=CC=2C=CC=CC=2)=C1S(O)(=O)=O ZTGKHKPZSMMHNM-UHFFFAOYSA-N 0.000 description 1
- YPBVPJBVLWXKLN-UHFFFAOYSA-N 3-(bromomethyl)-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=NC=CC=C1CBr YPBVPJBVLWXKLN-UHFFFAOYSA-N 0.000 description 1
- IITFKXZMISIFDX-UHFFFAOYSA-N 3-(bromomethyl)-2-chloro-1H-isoquinoline Chemical compound BrCC=1N(CC2=CC=CC=C2C=1)Cl IITFKXZMISIFDX-UHFFFAOYSA-N 0.000 description 1
- HXNJVBBHAGFQEL-UHFFFAOYSA-N 3-(bromomethyl)-5-(trifluoromethyl)pyridine Chemical compound BrCC=1C=NC=C(C=1)C(F)(F)F HXNJVBBHAGFQEL-UHFFFAOYSA-N 0.000 description 1
- CNQCWYFDIQSALX-UHFFFAOYSA-N 3-(chloromethyl)pyridine Chemical compound ClCC1=CC=CN=C1 CNQCWYFDIQSALX-UHFFFAOYSA-N 0.000 description 1
- WZIYCIBURCPKAR-UHFFFAOYSA-N 4-(chloromethyl)pyridine Chemical compound ClCC1=CC=NC=C1 WZIYCIBURCPKAR-UHFFFAOYSA-N 0.000 description 1
- UBUXDOBRSSOEOR-UHFFFAOYSA-N 4-chloro-3-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CN=CC=C1Cl UBUXDOBRSSOEOR-UHFFFAOYSA-N 0.000 description 1
- LNONDJJKAWIUCO-UHFFFAOYSA-N 5-(3-hydroxypropoxy)-2-methyl-7-(naphthalen-1-ylmethoxy)chromen-4-one Chemical compound OCCCOC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C)=O LNONDJJKAWIUCO-UHFFFAOYSA-N 0.000 description 1
- ZDXXBQCPEINOJN-UHFFFAOYSA-N 5-(3-hydroxypropoxy)-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCCCOC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O ZDXXBQCPEINOJN-UHFFFAOYSA-N 0.000 description 1
- JOKXNPBUJWVUAR-UHFFFAOYSA-N 5-(3-hydroxypropylamino)-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCCCNC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O JOKXNPBUJWVUAR-UHFFFAOYSA-N 0.000 description 1
- CKYXDZTXUVWNEJ-UHFFFAOYSA-N 5-(4-hydroxybut-2-ynoxy)-2-propan-2-yl-7-(quinolin-4-ylmethoxy)chromen-4-one Chemical compound OCC#CCOC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=NC2=CC=CC=C12)C(C)C)=O CKYXDZTXUVWNEJ-UHFFFAOYSA-N 0.000 description 1
- TWCGGHVUACLEAU-UHFFFAOYSA-N 5-(4-hydroxybutyl)-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCCCCC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O TWCGGHVUACLEAU-UHFFFAOYSA-N 0.000 description 1
- DKWJEIGBANIPOQ-UHFFFAOYSA-N 5-(4-hydroxybutylamino)-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCCCCNC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O DKWJEIGBANIPOQ-UHFFFAOYSA-N 0.000 description 1
- LKBZTUDNNWGZHD-UHFFFAOYSA-N 5-(5-hydroxypentyl)-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCCCCCC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O LKBZTUDNNWGZHD-UHFFFAOYSA-N 0.000 description 1
- ZTODPMPMBIFEIF-UHFFFAOYSA-N 5-(5-hydroxypentylamino)-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCCCCCNC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O ZTODPMPMBIFEIF-UHFFFAOYSA-N 0.000 description 1
- SOILBLIIPUYFLH-UHFFFAOYSA-N 5-(bromomethyl)-1,3-thiazole Chemical compound BrCC1=CN=CS1 SOILBLIIPUYFLH-UHFFFAOYSA-N 0.000 description 1
- PPPCEAMFCKQRHG-UHFFFAOYSA-N 5-(bromomethyl)pyrimidine Chemical compound BrCC1=CN=CN=C1 PPPCEAMFCKQRHG-UHFFFAOYSA-N 0.000 description 1
- VUKUTFGJDRYKLT-UHFFFAOYSA-N 5-[2-fluoro-3-(hydroxymethyl)phenyl]-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound FC1=C(C=CC=C1CO)C1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O VUKUTFGJDRYKLT-UHFFFAOYSA-N 0.000 description 1
- AXPCAIBYKJJJBM-UHFFFAOYSA-N 5-[2-fluoro-5-(hydroxymethyl)phenyl]-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound FC1=C(C=C(C=C1)CO)C1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O AXPCAIBYKJJJBM-UHFFFAOYSA-N 0.000 description 1
- YOBAWQDONBLJOD-UHFFFAOYSA-N 5-[3-(2-hydroxyethyl)phenyl]-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCCC=1C=C(C=CC=1)C1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O YOBAWQDONBLJOD-UHFFFAOYSA-N 0.000 description 1
- LBRFYSPYJLEOPJ-UHFFFAOYSA-N 5-[3-(hydroxymethyl)anilino]-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCC=1C=C(C=CC=1)NC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O LBRFYSPYJLEOPJ-UHFFFAOYSA-N 0.000 description 1
- FAHMDEDCCMVORZ-UHFFFAOYSA-N 5-[3-(hydroxymethyl)phenyl]-2-propan-2-yl-7-quinolin-4-yloxychromen-4-one Chemical compound OCC=1C=C(C=CC=1)C1=C2C(C=C(OC2=CC(=C1)OC1=CC=NC2=CC=CC=C12)C(C)C)=O FAHMDEDCCMVORZ-UHFFFAOYSA-N 0.000 description 1
- LLZPZIQHEQWIEM-UHFFFAOYSA-N 5-[3-(hydroxymethyl)phenyl]-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCC=1C=C(C=CC=1)C1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O LLZPZIQHEQWIEM-UHFFFAOYSA-N 0.000 description 1
- WIJNDPMLKWIXGX-UHFFFAOYSA-N 5-[4-(hydroxymethyl)piperidin-1-yl]-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCC1CCN(CC1)C1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C(C)C)=O WIJNDPMLKWIXGX-UHFFFAOYSA-N 0.000 description 1
- UPDYFWGYADFTLE-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-methyl-7-quinolin-4-yloxychromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OC2=CC=NC3=CC=CC=C23)C)=O)C=CC=C1 UPDYFWGYADFTLE-UHFFFAOYSA-N 0.000 description 1
- WAAXDKOXEVMVGW-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-(1,3-thiazol-5-ylmethoxy)chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC2=CN=CS2)C(C)C)=O)C=CC=C1 WAAXDKOXEVMVGW-UHFFFAOYSA-N 0.000 description 1
- LEKQIINUAQEITG-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-(pyridin-2-ylmethoxy)chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC2=NC=CC=C2)C(C)C)=O)C=CC=C1 LEKQIINUAQEITG-UHFFFAOYSA-N 0.000 description 1
- ZZJYXRFCTAZZOU-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-(pyridin-3-ylmethoxy)chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC=2C=NC=CC=2)C(C)C)=O)C=CC=C1 ZZJYXRFCTAZZOU-UHFFFAOYSA-N 0.000 description 1
- HHUPDRUOXXGHGA-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-(pyridin-4-ylmethoxy)chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC2=CC=NC=C2)C(C)C)=O)C=CC=C1 HHUPDRUOXXGHGA-UHFFFAOYSA-N 0.000 description 1
- YVZXCVSKXUXBSY-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-(pyrimidin-5-ylmethoxy)chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC=2C=NC=NC=2)C(C)C)=O)C=CC=C1 YVZXCVSKXUXBSY-UHFFFAOYSA-N 0.000 description 1
- VDXJXRAJHDVIGB-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-(quinolin-2-ylmethoxy)chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC2=NC3=CC=CC=C3C=C2)C(C)C)=O)C=CC=C1 VDXJXRAJHDVIGB-UHFFFAOYSA-N 0.000 description 1
- IQBKBVFUHIFYAO-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-(quinolin-4-ylmethoxy)chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC2=CC=NC3=CC=CC=C23)C(C)C)=O)C=CC=C1 IQBKBVFUHIFYAO-UHFFFAOYSA-N 0.000 description 1
- WYGCOZHSWANUIV-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-(quinolin-6-ylmethoxy)chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC=2C=C3C=CC=NC3=CC=2)C(C)C)=O)C=CC=C1 WYGCOZHSWANUIV-UHFFFAOYSA-N 0.000 description 1
- GXGYKCHCBDVYAR-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-(quinolin-8-ylmethoxy)chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC=2C=CC=C3C=CC=NC=23)C(C)C)=O)C=CC=C1 GXGYKCHCBDVYAR-UHFFFAOYSA-N 0.000 description 1
- VDRAGUJZHQVMKP-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-[3-(trifluoromethyl)pyridin-2-yl]oxychromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OC2=NC=CC=C2C(F)(F)F)C(C)C)=O)C=CC=C1 VDRAGUJZHQVMKP-UHFFFAOYSA-N 0.000 description 1
- XIXFCSJVPRNNKN-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-[3-(trifluoromethyl)pyridin-4-yl]oxychromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OC2=C(C=NC=C2)C(F)(F)F)C(C)C)=O)C=CC=C1 XIXFCSJVPRNNKN-UHFFFAOYSA-N 0.000 description 1
- QZPJSWVTSQLEKY-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-[[2-(trifluoromethyl)pyridin-3-yl]methoxy]chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC=2C(=NC=CC=2)C(F)(F)F)C(C)C)=O)C=CC=C1 QZPJSWVTSQLEKY-UHFFFAOYSA-N 0.000 description 1
- GOEOLZXJGHPMKV-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-[[3-(trifluoromethyl)phenyl]methoxy]chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC2=CC(=CC=C2)C(F)(F)F)C(C)C)=O)C=CC=C1 GOEOLZXJGHPMKV-UHFFFAOYSA-N 0.000 description 1
- FNKGUSQMHUWDEH-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-[[5-(trifluoromethyl)pyridin-3-yl]methoxy]chromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC=2C=NC=C(C=2)C(F)(F)F)C(C)C)=O)C=CC=C1 FNKGUSQMHUWDEH-UHFFFAOYSA-N 0.000 description 1
- UIVKQHYNBYKGRM-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-yl-7-quinolin-4-yloxychromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OC2=CC=NC3=CC=CC=C23)C(C)C)=O)C=CC=C1 UIVKQHYNBYKGRM-UHFFFAOYSA-N 0.000 description 1
- UQUKKNCRPQORLM-UHFFFAOYSA-N 5-[[2-(hydroxymethyl)phenyl]methoxy]-7-(naphthalen-1-ylmethoxy)-2-propan-2-ylchromen-4-one Chemical compound OCC1=C(COC2=C3C(C=C(OC3=CC(=C2)OCC2=CC=CC3=CC=CC=C23)C(C)C)=O)C=CC=C1 UQUKKNCRPQORLM-UHFFFAOYSA-N 0.000 description 1
- ZPTNKPYDDZEAPA-UHFFFAOYSA-N 6-(bromomethyl)quinoline Chemical compound N1=CC=CC2=CC(CBr)=CC=C21 ZPTNKPYDDZEAPA-UHFFFAOYSA-N 0.000 description 1
- JAWCFVCIFHFODD-UHFFFAOYSA-N 7-[(1-chloroisoquinolin-4-yl)methoxy]-5-[[2-(hydroxymethyl)phenyl]methoxy]-2-propan-2-ylchromen-4-one Chemical compound ClC1=NC=C(C2=CC=CC=C12)COC1=CC(=C2C(C=C(OC2=C1)C(C)C)=O)OCC1=C(C=CC=C1)CO JAWCFVCIFHFODD-UHFFFAOYSA-N 0.000 description 1
- IAAUGSYGHOFWEW-UHFFFAOYSA-N 8-(bromomethyl)quinoline Chemical compound C1=CN=C2C(CBr)=CC=CC2=C1 IAAUGSYGHOFWEW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 102000034263 Amino acid transporters Human genes 0.000 description 1
- 108050005273 Amino acid transporters Proteins 0.000 description 1
- PDXZPHORWJFKEP-WRDXTXOZSA-N C/C(/C=N)=C(\C=CC=C1)/C1=N Chemical compound C/C(/C=N)=C(\C=CC=C1)/C1=N PDXZPHORWJFKEP-WRDXTXOZSA-N 0.000 description 1
- JXSLTIGOYZLJDF-CZKVRAMASA-N C/C(/C=N)=C1\N=CC=CC1=N Chemical compound C/C(/C=N)=C1\N=CC=CC1=N JXSLTIGOYZLJDF-CZKVRAMASA-N 0.000 description 1
- BSGVAUFIGACOTB-HJOZHYCISA-N CC(C)C(C)/N=C(/C)\N=N/N=N Chemical compound CC(C)C(C)/N=C(/C)\N=N/N=N BSGVAUFIGACOTB-HJOZHYCISA-N 0.000 description 1
- KXPONPDBUIMQBV-UHFFFAOYSA-N CC(C)C(OC(C1)=C2C(OCc3ccccc3CO)=CC1OCc1ccncc1)=CC2=O Chemical compound CC(C)C(OC(C1)=C2C(OCc3ccccc3CO)=CC1OCc1ccncc1)=CC2=O KXPONPDBUIMQBV-UHFFFAOYSA-N 0.000 description 1
- SETKNWLTQKACKE-UHFFFAOYSA-N CC(C)c1cccc2c1ncnc2 Chemical compound CC(C)c1cccc2c1ncnc2 SETKNWLTQKACKE-UHFFFAOYSA-N 0.000 description 1
- REJVUKQHOATCSS-UHFFFAOYSA-N CC(C)c1ccnc2ncccc12 Chemical compound CC(C)c1ccnc2ncccc12 REJVUKQHOATCSS-UHFFFAOYSA-N 0.000 description 1
- QKBPWLUTKZLRRM-UHFFFAOYSA-N Cc1c(C=NCC2)c2ccn1 Chemical compound Cc1c(C=NCC2)c2ccn1 QKBPWLUTKZLRRM-UHFFFAOYSA-N 0.000 description 1
- MUDSDYNRBDKLGK-UHFFFAOYSA-N Cc1c(cccc2)c2ncc1 Chemical compound Cc1c(cccc2)c2ncc1 MUDSDYNRBDKLGK-UHFFFAOYSA-N 0.000 description 1
- JWEOEZZCZCCPJL-UHFFFAOYSA-N Cc1c(cccc2)c2ncn1 Chemical compound Cc1c(cccc2)c2ncn1 JWEOEZZCZCCPJL-UHFFFAOYSA-N 0.000 description 1
- ZKALJIDUBQLBDE-UHFFFAOYSA-N Cc1c(cccn2)c2ccn1 Chemical compound Cc1c(cccn2)c2ccn1 ZKALJIDUBQLBDE-UHFFFAOYSA-N 0.000 description 1
- QHRZMGDJNNDMGZ-UHFFFAOYSA-N Cc1c(ccnc2)c2ccc1 Chemical compound Cc1c(ccnc2)c2ccc1 QHRZMGDJNNDMGZ-UHFFFAOYSA-N 0.000 description 1
- BWWVJXOALCFZCR-UHFFFAOYSA-N Cc1c(ccnc2)c2ccn1 Chemical compound Cc1c(ccnc2)c2ccn1 BWWVJXOALCFZCR-UHFFFAOYSA-N 0.000 description 1
- NUWRWVNNXLNLIB-UHFFFAOYSA-N Cc1c(ccnc2)c2ncc1 Chemical compound Cc1c(ccnc2)c2ncc1 NUWRWVNNXLNLIB-UHFFFAOYSA-N 0.000 description 1
- NVIRFBFIFVSTCT-UHFFFAOYSA-N Cc1c(cncc2)c2ncc1 Chemical compound Cc1c(cncc2)c2ncc1 NVIRFBFIFVSTCT-UHFFFAOYSA-N 0.000 description 1
- YNDGNDSFWJAXST-UHFFFAOYSA-N Cc1c(cncn2)c2ccc1 Chemical compound Cc1c(cncn2)c2ccc1 YNDGNDSFWJAXST-UHFFFAOYSA-N 0.000 description 1
- GGOGANXZRQOYHV-UHFFFAOYSA-N Cc1c2ncccc2ncc1 Chemical compound Cc1c2ncccc2ncc1 GGOGANXZRQOYHV-UHFFFAOYSA-N 0.000 description 1
- CQLOYHZZZCWHSG-UHFFFAOYSA-N Cc1c2nccnc2ccc1 Chemical compound Cc1c2nccnc2ccc1 CQLOYHZZZCWHSG-UHFFFAOYSA-N 0.000 description 1
- OVNPBRFCSAKOKV-UHFFFAOYSA-N Cc1c2nccnc2ccn1 Chemical compound Cc1c2nccnc2ccn1 OVNPBRFCSAKOKV-UHFFFAOYSA-N 0.000 description 1
- PXIGKUHOENGEJX-UHFFFAOYSA-N Cc1c2nccnc2ncc1 Chemical compound Cc1c2nccnc2ncc1 PXIGKUHOENGEJX-UHFFFAOYSA-N 0.000 description 1
- ZGWPLACLHCKVQQ-UHFFFAOYSA-N Cc1c2nnccc2ccn1 Chemical compound Cc1c2nnccc2ccn1 ZGWPLACLHCKVQQ-UHFFFAOYSA-N 0.000 description 1
- SHKCZDHARKWCSO-UHFFFAOYSA-N Cc1c2nnccc2ncc1 Chemical compound Cc1c2nnccc2ncc1 SHKCZDHARKWCSO-UHFFFAOYSA-N 0.000 description 1
- JJALJSWRWTVJCW-UHFFFAOYSA-N Cc1c2nnccc2ncn1 Chemical compound Cc1c2nnccc2ncn1 JJALJSWRWTVJCW-UHFFFAOYSA-N 0.000 description 1
- LMYVCXSKCQSIEQ-UHFFFAOYSA-N Cc1cccc2c1cccn2 Chemical compound Cc1cccc2c1cccn2 LMYVCXSKCQSIEQ-UHFFFAOYSA-N 0.000 description 1
- OJSSFUDHPGIKMO-UHFFFAOYSA-N Cc1cccc2c1ccnn2 Chemical compound Cc1cccc2c1ccnn2 OJSSFUDHPGIKMO-UHFFFAOYSA-N 0.000 description 1
- SVSYTDAHZIRUPE-UHFFFAOYSA-N Cc1ccnc2c1ccnn2 Chemical compound Cc1ccnc2c1ccnn2 SVSYTDAHZIRUPE-UHFFFAOYSA-N 0.000 description 1
- NFNJCQZTGVBMQL-UHFFFAOYSA-N Cc1ccnc2c1cncn2 Chemical compound Cc1ccnc2c1cncn2 NFNJCQZTGVBMQL-UHFFFAOYSA-N 0.000 description 1
- PBYMYAJONQZORL-UHFFFAOYSA-N Cc1nccc2c1cccc2 Chemical compound Cc1nccc2c1cccc2 PBYMYAJONQZORL-UHFFFAOYSA-N 0.000 description 1
- LYKKNBIZEKQROR-UHFFFAOYSA-N Cc1ncnc2c1cncn2 Chemical compound Cc1ncnc2c1cncn2 LYKKNBIZEKQROR-UHFFFAOYSA-N 0.000 description 1
- WESDBLALURHRDL-UHFFFAOYSA-N Cc1ncnc2c1nccn2 Chemical compound Cc1ncnc2c1nccn2 WESDBLALURHRDL-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101000577121 Homo sapiens Monocarboxylate transporter 3 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- CBRFQPNVIBRJQT-UHFFFAOYSA-N OC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C)=O Chemical compound OC1=C2C(C=C(OC2=CC(=C1)OCC1=CC=CC2=CC=CC=C12)C)=O CBRFQPNVIBRJQT-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 229920001774 Perfluoroether Chemical group 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000037323 Rare tumor Diseases 0.000 description 1
- WBTCZXYOKNRFQX-UHFFFAOYSA-N S1(=O)(=O)NC1=O Chemical group S1(=O)(=O)NC1=O WBTCZXYOKNRFQX-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JDBQNNKIOFSPOA-UHFFFAOYSA-N [2-(bromomethyl)phenyl]methanol Chemical compound OCC1=CC=CC=C1CBr JDBQNNKIOFSPOA-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical group N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- OTJZCIYGRUNXTP-UHFFFAOYSA-N but-3-yn-1-ol Chemical compound OCCC#C OTJZCIYGRUNXTP-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002170 ethers Chemical group 0.000 description 1
- CIZZUEUKGNBQPP-UHFFFAOYSA-N ethyl 2-anilino-7-oxo-8-phenylpteridine-6-carboxylate Chemical compound N1=C2N(C=3C=CC=CC=3)C(=O)C(C(=O)OCC)=NC2=CN=C1NC1=CC=CC=C1 CIZZUEUKGNBQPP-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000012105 intracellular pH reduction Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- YVRRBEBWSWMXCD-UHFFFAOYSA-N pyrrolo[3,2-c]pyridazin-3-one Chemical class N1=NC(=O)C=C2N=CC=C21 YVRRBEBWSWMXCD-UHFFFAOYSA-N 0.000 description 1
- LGOOLCMGKKGBHW-UHFFFAOYSA-N pyrrolo[3,2-d]pyrimidine-2,4-dione Chemical class O=C1NC(=O)C2=NC=CC2=N1 LGOOLCMGKKGBHW-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical group NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 150000008053 sultones Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本出願は、2015年1月22日に出願された米国特許仮出願第62/106,465号の優先権を主張し、この仮出願の開示内容は引用によりその全体が本明細書に組み込まれる。
本発明は、米国立衛生研究所によって付与されたR01 CA154739での政府による補助を伴ってなされた。米国政府は、本発明において一定の権利を有する。
悪性細胞は高度に同化作用性であり、その成長と生存に必要とされる成分を合成するために非常に高レベルの栄養分、ATPおよび構成ブロックを必要とし、必要とする。解糖経路の使用によりATPがもたらされるが、乳酸の生成もまた駆動され、乳酸は解糖経路の最後にピルビン酸から生成される。腫瘍細胞による大量の乳酸生成には、その消費または除去のため(がん細胞の細胞内酸性化を抑制するため)の効率的な手段が必要とされる。
R1はH、直鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C7)シクロアルキルまたは(C1〜C6)フルオロアルキルであり;
R2はH、直鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C7)シクロアルキルもしくは(C1〜C6)フルオロアルキル、(C6〜C10)アリール環系、5〜9員のヘテロアリール環系、(C1〜C6)アルキル−(C6〜C10)アリール環系または(C1〜C6)アルキル−(5〜9員の)ヘテロアリール環系である;
ただし、R2がアリール環系またはヘテロアリール環系を含むものである場合、該環系は、フルオロ、クロロ、トリフルオロメチル、(C1〜C6)アルコキシおよび(C1〜C6)フルオロアルコキシからなる群より独立して選択される0〜2個の置換基を有しているものとし;
ZはO、CH2、CH(CH3)、S、NH、N((C1〜C6)アルキル)、OCH2、OCH(CH3)、CH2S、CH(CH3)S、CH2NH、CH(CH3)NH、CH2N(CH3)またはCH(CH3)N(CH3)であり;
R3は単環式もしくは二環式の(C6〜C10)アリールまたは単環式もしくは二環式の(5〜10員の)ヘテロアリールであり、該アリールまたはヘテロアリールは置換されていても非置換であってもよく;
LはO、(CH2)m(ここで、m=1もしくは2)、CH((C1〜C6)アルキル)、CH((C3〜C7)シクロアルキル)、CH((C1〜C6)アルキル)CH2、S、NH、N((C1〜C6)アルキル)、OCH2、OCH((C1〜C6)アルキル)、SCH2、SCH((C1〜C6)アルキル)、CH2NH、CH2N((C1〜C6)アルキル)、CH(CH3)NH、CH(CH3)N((C1〜C6)アルキル)または結合であり;
R4は、式(IIA)
またはR4は、式(IIB)
またはR4は、式(IIC)
Lに結合している環の炭素原子は、Lに直接結合していてもよく、3〜7個の炭素原子を含むアルキレンリンカーのテザリングを介してLに結合していてもよく、前記3〜7個の炭素原子の2個のうち1個が、O、NH、N(C1〜C6)アルキルもしくはN(C1〜C6)フルオロアルキルからなる群より選択される独立して選択されるヘテロ原子で置き換えられていてもよいか;
またはR4は、式(IID)
の化合物またはその薬学的に許容され得る塩を提供する。さらに、本発明により、本発明のいずれか1つの化合物および薬学的に許容され得る賦形剤を含む医薬組成物を提供する。
R1はH、直鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C7)シクロアルキルまたは(C1〜C6)フルオロアルキルであり;
R2はH、直鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C7)シクロアルキルもしくは(C1〜C6)フルオロアルキル、(C6〜C10)アリール環系、5〜9員のヘテロアリール環系、(C1〜C6)アルキル−(C6〜C10)アリール環系または(C1〜C6)アルキル−(5〜9員の)ヘテロアリール環系である;
ただし、R2がアリール環系またはヘテロアリール環系を含むものである場合、該環系は、フルオロ、クロロ、トリフルオロメチル、(C1〜C6)アルコキシおよび(C1〜C6)フルオロアルコキシからなる群より独立して選択される0〜2個の置換基を有しているものとし;
ZはO、CH2、CH(CH3)、S、NH、N((C1〜C6)アルキル)、OCH2、OCH(CH3)、CH2S、CH(CH3)S、CH2NH、CH(CH3)NH、CH2N(CH3)またはCH(CH3)N(CH3)であり;
R3は単環式もしくは二環式の(C6〜C10)アリールまたは単環式もしくは二環式の(5〜10員の)ヘテロアリールであり、該アリールまたはヘテロアリールは置換されていても非置換であってもよく;
LはO、(CH2)m(ここで、m=1もしくは2)、CH((C1〜C6)アルキル)、CH((C3〜C7)シクロアルキル)、CH((C1〜C6)アルキル)CH2、S、NH、N((C1〜C6)アルキル)、OCH2、OCH((C1〜C6)アルキル)、SCH2、SCH((C1〜C6)アルキル)、CH2NH、CH2N((C1〜C6)アルキル)、CH(CH3)NH、CH(CH3)N((C1〜C6)アルキル)または結合であり;
R4は、式(IIA)
またはR4は、式(IIB)
またはR4は、式(IIC)
Lに結合している環の炭素原子は、Lに直接結合していてもよく、3〜7個の炭素原子を含むアルキレンリンカーのテザリングを介してLに結合していてもよく、前記3〜7個の炭素原子の2個のうち1個が、O、NH、N(C1〜C6)アルキルもしくはN(C1〜C6)フルオロアルキルからなる群より選択される独立して選択されるヘテロ原子で置き換えられていてもよいか;
またはR4は、式(IID)
のいくつかの新規なMCT阻害薬またはその薬学的に許容され得る塩を見出した。
ここで、XはH、(C1〜C6)アルキルまたはCF3であり;
Yは存在していてもよく、Yが存在している場合、Yは、1〜3個の場合があり、F、Cl、Br、CF3、(C1〜C6)アルキル、O(C1〜C6)アルキル、NH2、NH(C1〜C6)アルキル、N((C1〜C6)アルキル)2、NH−(CH2)j−CH2−Qならびに
からなる群より選択される置換基である。
Yは存在していてもよく、Yが存在している場合、Yは、1〜3個の場合があり、F、Cl、Br、CF3、(C1〜C6)アルキル、O(C1〜C6)アルキル、NH2、NH(C1〜C6)アルキル、N((C1〜C6)アルキル)2、NH−(CH2)j−CH2−Qならびに
からなる群より選択される置換基であり、Yは、多環系のどの環に配置されていてもよい。
Yは存在していてもよく、Yが存在している場合、Yは、1〜3個の場合があり、F、Cl、Br、CF3、(C1〜C6)アルキル、O(C1〜C6)アルキル、NH2、NH(C1〜C6)アルキル、N((C1〜C6)アルキル)2、NH−(CH2)j−CH2−Qならびに
からなる群より選択される置換基であり、Yは、多環系のどの環に配置されていてもよい。
式中、波線は式(IIC)における該環の結合点を示し;
各Mは独立して炭素原子または窒素原子であり、ここで、Mは1つまたは2つの場合において窒素原子であり;
GはS、O、NH、N(C1〜C6)アルキルまたはN(CF3)であり;
Tは独立して、各存在において炭素原子または窒素原子である;
ただし、MまたはTが炭素原子である場合、該炭素原子は水素またはR6基を有するものであるものとする。
この一般的な骨格の型は、構造1(表2)に示した親構造にちなんで「クロメノン」または「4−クロメノン」と称される。クロメノン環系のナンバリングシステムを構造2において示す。この骨格は、天然産物であるフラボンファミリー(構造3が構成員の親である)と構造的に関連しているが、R2=Phでなければフラボンファミリーと相違する。フラボンはすべて、クロメノン環系の2位にフェニル基を有し、このファミリーのほとんどの構成員はポリヒドロキシル化型である。適切に置換されたフラボノイドはMCT阻害薬であることが報告されている33,34(例えば、天然産物のルテオリン(4))が、活性には複数のフェノール基が必須であり、これはC−2フェニル環にO−メチル化を有する類似体またはこの環にヒドロキシル基が1つしかない類似体は有意に低活性であるという所見33から明らかである。フラボンのヒドロキシル化類似体は本発明の特許請求の範囲に含まれない。
反応はすべて、特に記載のない限り、ゴム隔膜を取り付けた火炎乾燥したガラス器具内で、陽圧の窒素またはアルゴン下で行なった。テトラヒドロフラン、DMF、アセトニトリルおよび塩化メチレンはAldrichから購入し、受け取った状態のまま使用した。
工程2.
工程3.
[実施例2]
5−(3−ヒドロキシプロポキシ)−2−メチル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例3]
5−(4−ヒドロキシブトキシ)−2−メチル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例4]
5−(2,3−ジヒドロキシプロポキシ)−2−メチル−7−(キノリン−4−イルオキシ)−4H−クロメン−4−オン
[実施例5]
5−(4−ヒドロキシブトキシ)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
工程2.
実施例2の場合のように、1−ブロモメチルナフタレンを第1アルキル化剤に使用した。
工程3.実施例3の場合のように、4−ブロモ−1−ブタノールを第2アルキル化剤として使用。
[実施例6]
5−(3−ヒドロキシプロポキシ)−2−イソプロピル−7−(キノリン−4−イルメトキシ)−4H−クロメン−4−オン
最終生成物5−(3−ヒドロキシプロポキシ)−2−イソプロピル−7−(キノリン−4−イルメトキシ)−4H−クロメン−4−オン:白色固形物の裏付けデータ。LC−MS(ESI):m/z 420[M+1]+;1H NMR(400MHz,CD3OD)δ(ppm)1.21(d,J=6.8Hz,6H),1.99−2.02(m,2H),2.77(七重項,J=6.8Hz,1H),3.74(t,J=5.4Hz,2H),4.16(t,J=6.0Hz,2H),5.88(s,2H),5.95(s,1H),6.69(d,J=2.4Hz,1H),6.86(d,J=2.4Hz,1H),7.81−8.33(m,5H),8.99(d,J=5.2Hz,1H).
[実施例7]
5−(3−ヒドロキシプロポキシ)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例8]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例9]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(キノリン−4−イルオキシ)−4H−クロメン−4−オン
[実施例10]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−((2−(トリフルオロメチル)ピリジン−3−イル)メトキシ)−4H−クロメン−4−オン
[実施例11]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−((3−(トリフルオロメチル)ピリジン−2−イル)オキシ)−4H−クロメン−4−オン
[実施例12]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−((3−(トリフルオロメチル)ベンジル)オキシ)−4H−クロメン−4−オン
[実施例13]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(ピリジン−2−イルメトキシ)−4H−クロメン−4−オン
[実施例14]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(ピリジン−3−イルメトキシ)−4H−クロメン−4−オン
[実施例15]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(ピリジン−4−イルメトキシ)−4H−クロメン−4−オン
[実施例16]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−((5−(トリフルオロメチル)ピリジン−3−イル)メトキシ)−4H−クロメン−4−オン
[実施例17]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−((3−(トリフルオロメチル)ピリジン−4−イル)オキシ)−4H−クロメン−4−オン
[実施例18]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(チアゾル−5−イルメトキシ)−4H−クロメン−4−オン
[実施例19]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(キノリン−8−イルメトキシ)−4H−クロメン−4−オン
[実施例20]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(キノリン−2−イルメトキシ)−4H−クロメン−4−オン
[実施例21]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(キノリン−6−イルメトキシ)−4H−クロメン−4−オン
[実施例22]
2−シクロプロピル−5−((2−(ヒドロキシメチル)ベンジル)オキシ)−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例23]
2−シクロプロピル−5−((2−(ヒドロキシメチル)ベンジル)オキシ)−7−((2−(トリフルオロメチル)ピリジン−3−イル)メトキシ)−4H−クロメン−4−オン
[実施例24]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(キノリン−4−イルメトキシ)−4H−クロメン−4−オン
[実施例25]
7−((1−クロロisoキノリン−4−イル)メトキシ)−5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−4H−クロメン−4−オン
[実施例26]
5−(3−ヒドロキシプロポキシ)−2−フェニル−7−(キノリン−4−イルオキシ)−4H−クロメン−4−オン
この実施例の最終生成物5−(3−ヒドロキシプロポキシ)−2−フェニル−7−(キノリン−4−イルオキシ)−4H−クロメン−4−オンの裏付けデータ:LC−MS(ESI):m/z 440[M+1]+;1H NMR(400MHz,CD3OD)δ(ppm)1.99−2.08(m,2H),3.77(t,J=5.4Hz,2H),4.18(t,J=6.0Hz,2H),6.77(s,1H),7.02(d,J=2.0Hz,1H),7.22(d,J=6.8Hz,1H),7.26(d,J=2.0Hz,,1H),7.45−7.49(m,3H),7.90−7.93(m,3H),8.09−8.11(m,2H),8.57(d,J=8.4Hz,1H),8.89(d,J=6.4Hz,1H).
[実施例27]
5−(2,3−ジヒドロキシプロポキシ)−2−フェニル−7−(キノリン−4−イルオキシ)−4H−クロメン−4−オン
この実施例の最終生成物5−(2,3−ジヒドロキシプロポキシ)−2−フェニル−7−(キノリン−4−イルオキシ)−4H−クロメン−4−オン:白色固形物の裏付けデータ。LC−MS(ESI):m/z 456[M+1]+;1H NMR(400MHz,CD3OD)δ(ppm)3.67(d,J=5.6Hz,2H),3.96−3.99(m,1H),4.11−4.13(m,2H),6.80(s,1H),7.05(d,J=2.4Hz,1H),7.22(d,J=6.4Hz,1H),7.28(d,J=2.4Hz,1H),7.45−7.50(m,3H),7.89−7.94(m,3H),8.05−8.11(m,2H),8.56(d,J=8.4Hz,1H),8.88(d,J=6.4Hz,1H).
[実施例28]
5−(3−ヒドロキシプロポキシ)−7−(ナフタレン−1−イルメトキシ)−2−フェニル−4H−クロメン−4−オン
この中間体:黄色固形物の裏付けデータ。Rf=0.18(EA:ヘキサン=1:4);LC−MS(ESI)m/z 395[M+1]+.
この実施例の最終生成物5−(3−ヒドロキシプロポキシ)−7−(ナフタレン−1−イルメトキシ)−2−フェニル−4H−クロメン−4−オン:白色固形物の裏付けデータ。LC−MS(ESI):m/z 453[M+1]+
[実施例29]
5−(4−ヒドロキシブトキシ)−7−(ナフタレン−1−イルメトキシ)−2−フェニル−4H−クロメン−4−オン
[実施例30]
5−(4−ヒドロキシブトキシ)−2−イソプロピル−7−(キノリン−4−イルメトキシ)−4H−クロメン−4−オン
5−(4−ヒドロキシブトキシ)−2−イソプロピル−7−(キノリン−4−イルメトキシ)−4H−クロメン−4−オンを得るための還元:5−((4−ヒドロキシブト−2−イン−1−イル)オキシ)−2−イソプロピル−7−(キノリン−4−イルメトキシ)−4H−クロメン−4−オン(27mg,0.063mmol)をTHF(5mL)とMeOH(10mL)中に含む溶液をPd/C(10mg,10%)で処理した。得られた混合物をH2雰囲気下で30分間、水素化した。反応液を濾過し、粗製生成物を分取HPLCによって精製し、5−(4−ヒドロキシブトキシ)−2−イソプロピル−7−(キノリン−4−イルメトキシ)−4H−クロメン−4−オンを白色固形物として得た。裏付けデータ:LC−MS(ESI):m/z 434[M+1]+;1H NMR(400MHz,CD3OD)δ(ppm)1.21(d,J=6.8Hz,6H),1.65−1.71(m,2H),1.84−1.89(m,2H),2.76(七重項,J=6.8Hz,1H),3.55(t,J=6.4Hz,2H),4.07(t,J=6.0Hz,2H),5.87(s,2H),5.94(s,1H),6.56(d,J=2.4Hz,1H),6.84(d,J=2.4Hz,1H),7.80−8.32(m,5H),8.99(d,J=4.4Hz,1H).
[実施例31]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−メチル−7−(キノリン−4−イルオキシ)−4H−クロメン−4−オン
[実施例32]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−((4−(トリフルオロメチル)ピリジン−2−イル)オキシ)−4H−クロメン−4−オン
[実施例33]
5−((2−(ヒドロキシメチル)ベンジル)オキシ)−2−イソプロピル−7−(ピリミジン−5−イルメトキシ)−4H−クロメン−4−オン
本発明の化合物を調製するために使用した合成中間体は、合成スキーム2に概要を示した手順によって調製した:
合成スキーム2
工程2:2−イソプロピル−4−オキソ−7−(((トリフルオロメチル)スルホニル)オキシ)−4H−クロメン−5−イルアセテート:
工程3:7−シアノ−2−イソプロピル−4−オキソ−4H−クロメン−5−イルアセテート:
工程4:5−ヒドロキシ−2−イソプロピル−4−オキソ−4H−クロメン−7−カルボン酸:
工程5:5−アセトキシ−2−イソプロピル−4−オキソ−4H−クロメン−7−カルボン酸:
工程6:7−(ヒドロキシメチル)−2−イソプロピル−4−オキソ−4H−クロメン−5−イルアセテート:
本発明の化合物は、合成スキーム2に概要を示した手順によって得られる中間体から合成スキーム3に概要を示した手順によって作製され得る:
合成スキーム3
工程2.5−ヒドロキシ−2−イソプロピル−7−((ナフタレン−1−イルオキシ)メチル)−4H−クロメン−4−オン:
工程3:5−(4−ヒドロキシブトキシ)−2−イソプロピル−7−((ナフタレン−1−イルオキシ)メチル)−4H−クロメン−4−オン:
また、本発明の化合物を、合成スキーム4に概要を示した手順によっても作製した。
[実施例37]
5−(5−ヒドロキシペンチル)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
また、本発明の化合物を、合成スキーム5に概要を示した手順によっても作製した:
合成スキーム5
[実施例39]
5−(2−クロロ−5−(ヒドロキシメチル)フェニル)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例40]
5−(2−フルオロ−5−(ヒドロキシメチル)フェニル)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例41]
5−(2−フルオロ−3−(ヒドロキシメチル)フェニル)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例42]
5−(3−(ヒドロキシメチル)フェニル)−2−イソプロピル−7−(キノリン−4−イルオキシ)−4H−クロメン−4−オン
[実施例43]
5−(3−(ヒドロキシメチル)フェニル)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
また、本発明の化合物を、合成スキーム6に概要を示した手順によっても作製した:
合成スキーム6
[実施例47]
5−((5−ヒドロキシペンチル)アミノ)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例48]
5−((3−ヒドロキシプロピル)アミノ)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例49]
5−((3−(ヒドロキシメチル)フェニル)アミノ)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
[実施例50]
5−(4−(ヒドロキシメチル)ピペリジン−1−イル)−2−イソプロピル−7−(ナフタレン−1−イルメトキシ)−4H−クロメン−4−オン
生物学的活性
本発明により、種々の実施形態において、モノカルボン酸トランスポータMCT1、モノカルボン酸トランスポータMCT4または両方を阻害する方法であって、該モノカルボン酸トランスポータを有効量または有効濃度の本発明の化合物と接触させることを含む方法を提供する。
選択された本発明の化合物の生物学的活性
本発明の化合物の具体的な実施例を、MCT1を高度発現し、小分子MCT阻害薬に対して感受性であることが知られている4細胞株であるRaji(バーキット)リンパ腫細胞の4日間バイアビリティのMTTアッセイを用いて測定した推定EC50値とともに表8に示す。アッセイプロトコルは文献4に記載のものに従う。また、本明細書に記載していないが当該技術分野において標準的である他のアッセイ、例えば、MCT基質である放射性標識した乳酸の輸送の競合的阻害のアッセイも、これらの化合物の作用機序の確立に有用であり得る。
用語MCT1およびMCT4は、それぞれモノカルボン酸トランスポータアイソフォーム1およびモノカルボン酸トランスポータアイソフォーム4をいう。
Claims (21)
- 式(IA)
(式中
R1はH、直鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C
7)シクロアルキルまたは(C1〜C6)フルオロアルキルであり;
R2はH、直鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C
7)シクロアルキルもしくは(C1〜C6)フルオロアルキル、(C6〜C10)アリー
ル環系、5〜9員のヘテロアリール環系、(C1〜C6)アルキル−(C6〜C10)ア
リール環系または(C1〜C6)アルキル−(5〜9員の)ヘテロアリール環系である;
ただし、R2がアリール環系またはヘテロアリール環系を含むものである場合、該環系
は、フルオロ、クロロ、トリフルオロメチル、(C1〜C6)アルコキシおよび(C1〜
C6)フルオロアルコキシからなる群より独立して選択される0〜2個の置換基を有して
いるものとし;
ZはO、CH2、CH(CH3)、S、NH、N((C1〜C6)アルキル)、OCH
2、OCH(CH3)、CH2S、CH(CH3)S、CH2NH、CH(CH3)NH
、CH2N(CH3)またはCH(CH3)N(CH3)であり;
R3は単環式もしくは二環式の(C6〜C10)アリールまたは単環式もしくは二環式
の(5〜10員の)ヘテロアリールであり、該アリールまたはヘテロアリールは置換され
ていても非置換であってもよく;
LはO、(CH2)m(ここで、m=1もしくは2)、CH((C1〜C6)アルキル
)、CH((C3〜C7)シクロアルキル)、CH((C1〜C6)アルキル)CH2、
S、NH、N((C1〜C6)アルキル)、OCH2、OCH((C1〜C6)アルキル
)、SCH2、SCH((C1〜C6)アルキル)、CH2NH、CH2N((C1〜C
6)アルキル)、CH(CH3)NH、CH(CH3)N((C1〜C6)アルキル)ま
たは結合であり;
R4は、式(IIA)
の基であり、ここで、波線は結合点を示し、n=0、1もしくは2であり;R5はH、直
鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C7)シクロアル
キルもしくは(C1〜C6)フルオロアルキルであり;R6はH、メチルもしくはOHで
あるか;
またはR4は、式(IIB)
の基であり、ここで、波線は結合点を示し、n=0、1もしくは2であり;R5はH、直
鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C7)シクロアル
キルもしくは(C1〜C6)フルオロアルキルであるか;
またはR4は、式(IIC)
の基であり、ここで、波線は結合点を示し、n=0、1もしくは2であり;R5はH、直
鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C7)シクロアル
キル、(C1〜C6)フルオロアルキル、(C6〜C10)アリール、もしくはNH、N
(C1〜C6)アルキル、OおよびSからなる群より選択される1個もしくは2個のヘテ
ロ原子を含む(4〜7員の)ヘテロシクリルであり;R6はハロ、(C1〜C6)アルキ
ル、(C1〜C6)アルコキシ、(C1〜C6)フルオロアルキルもしくは(C1〜C6
)フルオロアルコキシであり;ここで、該環は、(C6〜C10)アリールもしくは基L
の結合位置に炭素原子を含む(5〜9員の)ヘテロアリールであり、0〜3個の独立して
選択されるR6基が置換基として該環上に存在しているか;あるいは、該環は、非芳香族
のシクロアルキルもしくは基Lの結合位置に炭素原子を含むヘテロシクリル環であり、
Lに結合している環の炭素原子は、Lに直接結合していてもよく、3〜7個の炭素原子
を含むアルキレンリンカーによってLに結合していてもよく、前記3〜7個の炭素原子の2個のうち1個が、O、NH、N(C1〜C6)アルキルもしくはN(C
〜C6)フルオロアルキルからなる群より選択される独立して選択されるヘテロ原子で置
き換えられていてもよいか;
またはR4は、式(IID)
の基であり、ここで、波線は結合点を示し;n=0、1もしくは2であり;R5はH、直
鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C7)シクロアル
キル、(C1〜C6)フルオロアルキル、(C6〜C10)アリール、もしくはNH、N
(C1〜C6)アルキル、OおよびSからなる群より選択される1個もしくは2個のヘテ
ロ原子を含む(4〜7員の)ヘテロシクリルであり;R6はハロ、(C1〜C6)アルキ
ル、(C1〜C6)アルコキシ、(C1〜C6)フルオロアルキルもしくは(C1〜C6
)フルオロアルコキシであり;ここで、該環は、(5〜9員の)ヘテロシクリルもしくは
基Lの結合位置に窒素原子を含む(5〜9員の)ヘテロアリールであり、Lに結合してい
る環の窒素原子は、Lに直接結合していてもよく、3〜7個の炭素原子を含むアルキレン
リンカーによってLに結合していてもよく、前記3〜7個の炭素原子の2個のうち1個が、O、NH、N(C1〜C6)アルキルまたはN(C1〜C6)フルオロア
ルキルからなる群より選択される独立して選択されるヘテロ原子で置き換えられていても
よく;0〜3個の独立して選択されるR6基が置換基として該環上に存在している)
の化合物またはその薬学的に許容され得る塩。 - R2がH、直鎖(C1〜C6)アルキル、分枝鎖(C3〜C6)アルキル、(C3〜C
7)シクロアルキルまたは(C1〜C6)フルオロアルキルである、請求項1に記載の化
合物。 - 請求項1に記載の化合物および薬学的に許容され得る賦形剤を含む医薬組成物。
- モノカルボン酸トランスポータMCT1、モノカルボン酸トランスポータMCT4また
は両方を阻害するインビトロ方法であって、該モノカルボン酸トランスポータを有効量または有効濃度の請求項1に記載の化合物と接触させることを含むインビトロ方法。 - 有効量の請求項1に記載の化合物を含む、MCT1、MCT4または両方に対する阻害
薬効果を有する化合物での病状の処置が医学的に指示される、哺乳動物の該病状の処置の
ための組成物。 - 該化合物が抗腫瘍、抗糖尿病、抗炎症性または免疫抑制性の薬理学的効果を示すもので
ある、請求項10に記載の組成物。 - 哺乳動物がヒトである、請求項10に記載の組成物。
- 有効量のビグアニドと共に該哺乳動物に投与される、請求項10に記載の組成物。
- ビグアニドがメトホルミンである、請求項13に記載の組成物。
- 有効量の標準治療の治療用薬剤と共に、該哺乳動物に投与される、請求項10に記載の
組成物。 - 経口、静脈内、鼻腔内または経皮での方法によって投与される、請求項10に記載の組
成物。 - 病状がMCT1および/またはMCT4の高活性または高存在量を特徴とするものであ
る、請求項10に記載の組成物。 - 病状ががんまたはII型糖尿病である、請求項17に記載の組成物。
- 病状ががんであり、処置が腫瘍(1つまたは複数)におけるMCT1および/またはM
CT4の高発現レベルの測定後に行なわれる、請求項17に記載の組成物。 - ヒトの悪性腫瘍(1つまたは複数)の処置のための請求項1に記載の化合物を含む組成物。
- ヒトのII型糖尿病の処置のための請求項1に記載の化合物を含む組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562106465P | 2015-01-22 | 2015-01-22 | |
US62/106,465 | 2015-01-22 | ||
PCT/US2016/014455 WO2016118822A1 (en) | 2015-01-22 | 2016-01-22 | Chromenone inhibitors of monocarboxylate transporters |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018502875A JP2018502875A (ja) | 2018-02-01 |
JP6713472B2 true JP6713472B2 (ja) | 2020-06-24 |
Family
ID=56417787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017538317A Expired - Fee Related JP6713472B2 (ja) | 2015-01-22 | 2016-01-22 | クロメノンモノカルボン酸トランスポータ阻害薬 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9994555B2 (ja) |
EP (1) | EP3247349B1 (ja) |
JP (1) | JP6713472B2 (ja) |
CA (1) | CA2974694A1 (ja) |
WO (1) | WO2016118822A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6568301B2 (ja) * | 2016-02-29 | 2019-08-28 | 富士通フロンテック株式会社 | 撮像装置及び撮像方法 |
AU2019245334A1 (en) * | 2018-03-30 | 2020-10-08 | Nirogy Therapeutics, Inc. | Bicyclic enone carboxylates as modulators of transporters and uses thereof |
EP3784650B1 (en) * | 2018-04-25 | 2023-09-06 | Charles R. Drew University of Medicine and Science | N-phenyl-n'-(4-{[6-(1h-imidazol-1-yl)-4-pyrimidinyl]amino}phenyl)urea derivatives as mct4 inhibitors for the treatment of cancer |
WO2021249969A1 (en) * | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
CN115197201B (zh) * | 2021-11-12 | 2023-12-26 | 九江学院 | 一种含有胺基嘧啶环的白杨素衍生物及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160115146A1 (en) * | 2013-06-07 | 2016-04-28 | Universite Catholique De Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
-
2016
- 2016-01-22 WO PCT/US2016/014455 patent/WO2016118822A1/en active Application Filing
- 2016-01-22 US US15/545,117 patent/US9994555B2/en active Active
- 2016-01-22 JP JP2017538317A patent/JP6713472B2/ja not_active Expired - Fee Related
- 2016-01-22 EP EP16740815.2A patent/EP3247349B1/en active Active
- 2016-01-22 CA CA2974694A patent/CA2974694A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9994555B2 (en) | 2018-06-12 |
CA2974694A1 (en) | 2016-07-28 |
EP3247349B1 (en) | 2019-12-11 |
EP3247349A4 (en) | 2018-07-25 |
WO2016118822A1 (en) | 2016-07-28 |
US20180009792A1 (en) | 2018-01-11 |
JP2018502875A (ja) | 2018-02-01 |
EP3247349A1 (en) | 2017-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6713472B2 (ja) | クロメノンモノカルボン酸トランスポータ阻害薬 | |
JP7293560B2 (ja) | 芳香族ビニルまたは芳香族エチル系誘導体、その製造方法、中間体、薬物組成物および使用 | |
CA2961393A1 (en) | Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor | |
JP6725519B2 (ja) | 複素環式のモノカルボン酸トランスポータ阻害薬 | |
EP1660427A1 (en) | Substituted arylalkanoic acid derivative and use thereof | |
EP2161271A1 (en) | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | |
CA2659952A1 (en) | 8-hydroxyquinoline compounds and methods thereof | |
JP5331953B2 (ja) | 代謝性障害の治療のための3−アミノ−ピリジン誘導体 | |
JP6612882B2 (ja) | プテリジンジオンモノカルボン酸トランスポータ阻害薬 | |
CN113248474A (zh) | 五元氮唑杂环衍生物及其制备方法和用途 | |
US11465991B2 (en) | Pyrazole-containing macrophage migration inhibitory factor inhibitors | |
JP6199406B2 (ja) | ジアシルグリセロールアシルトランスフェラーゼ阻害剤としての新規化合物 | |
EP0905133A1 (en) | Tetrazole derivatives as LTD4 and H1 antagonists | |
CA3090829C (en) | Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof | |
JP2018039733A (ja) | 新規複素環誘導体 | |
CN111808080B (zh) | 取代的吡啶或嘧啶化合物、其制备方法及其在医药上的应用 | |
US11999723B2 (en) | Pyrazole-containing macrophage migration inhibitory factor inhibitors | |
KR20160006050A (ko) | 피롤로[1,2-a]피라진 유도체, 이의 약학적으로 허용가능한 염, 이들 화합물의 제조방법 및 이를 유효성분으로 함유하는 골다공증 치료 또는 예방용 약학조성물 | |
JP2024519334A (ja) | 三環式誘導体化合物の結晶形及びその製造方法並びにそれを含む薬学的組成物 | |
WO2022037601A1 (zh) | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途 | |
KR20200102565A (ko) | 피라졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171020 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190117 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191008 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200327 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200512 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200603 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6713472 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |